PA8613001A1 - Derivados de triazol sustituidos como antagonistas de oxitocina - Google Patents

Derivados de triazol sustituidos como antagonistas de oxitocina

Info

Publication number
PA8613001A1
PA8613001A1 PA20048613001A PA8613001A PA8613001A1 PA 8613001 A1 PA8613001 A1 PA 8613001A1 PA 20048613001 A PA20048613001 A PA 20048613001A PA 8613001 A PA8613001 A PA 8613001A PA 8613001 A1 PA8613001 A1 PA 8613001A1
Authority
PA
Panama
Prior art keywords
oxitocine
antagonists
derivatives replaced
triazol derivatives
inhibitors
Prior art date
Application number
PA20048613001A
Other languages
English (en)
Inventor
David Ellis
Alan Daniel Brown
Christopher Ronald Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0322159A external-priority patent/GB0322159D0/en
Priority claimed from GB0403150A external-priority patent/GB0403150D0/en
Priority claimed from GB0415110A external-priority patent/GB0415110D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PA8613001A1 publication Critical patent/PA8613001A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/10Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA CLASE DE 1,2,3-TRIAZOLES SUSTITUIDOS DE FORMULA (1) CON ACTIVIDAD COMO ANTAGONISTAS OXITOCINA, A SUS USOS , A PROCESOS PARA SU PREPARACION Y A COMPOSICIONES QUE CONTIENEN DICHO INHIBIDORES. ESTOS INHIBIDORES TIENEN UTILIDAD EN UNA DIVERSIDAD DE AREAS TERAPEUTICAS INCLUYENDO LA DISFUCION SEXUAL,PARTICULARMENTE LA EYACULACION PRECOZ (P.E.).
PA20048613001A 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina PA8613001A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0322159A GB0322159D0 (en) 2003-09-22 2003-09-22 New substituted triazoles for use as novel pharmaceuticals
GB0403150A GB0403150D0 (en) 2004-02-12 2004-02-12 Novel pharmaceuticals
GB0415110A GB0415110D0 (en) 2004-07-05 2004-07-05 Substituted triazole derivatives as oxytocin antagonists

Publications (1)

Publication Number Publication Date
PA8613001A1 true PA8613001A1 (es) 2005-08-04

Family

ID=34381637

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048613001A PA8613001A1 (es) 2003-09-22 2004-09-21 Derivados de triazol sustituidos como antagonistas de oxitocina

Country Status (12)

Country Link
EP (1) EP1673355A1 (es)
JP (1) JP2007505888A (es)
AR (1) AR045791A1 (es)
BR (1) BRPI0414663A (es)
CA (1) CA2539297C (es)
MX (1) MXPA06003158A (es)
NL (1) NL1027084C2 (es)
PA (1) PA8613001A1 (es)
PE (1) PE20050950A1 (es)
TW (1) TW200526606A (es)
UY (1) UY28524A1 (es)
WO (1) WO2005028452A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP2298748B1 (en) * 2004-11-18 2016-07-20 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
DE602006003416D1 (de) * 2005-03-21 2008-12-11 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP2301935A1 (en) 2005-07-09 2011-03-30 AstraZeneca AB (Publ) Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
WO2007017752A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
DE102006059710A1 (de) * 2006-12-18 2008-06-19 Freie Universität Berlin Substituierte 4-Hydroxypyridine
FR2910473B1 (fr) 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
MX2011003011A (es) 2008-09-22 2011-09-01 Cayman Chem Co Compuestos de multiheteroarilo como inhibidores de prostaglandina d sintasa hematopoyetica y su uso para tratar enfermedades mediadas por prostaglandina d2.
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida
CA3047643A1 (en) 2016-12-21 2018-06-28 Jiangsu Hengrui Medicine Co., Ltd. Condensed ring group azacyclobutyl triazole derivative, preparation method therefor and use thereof in medicine
TW201823231A (zh) 2016-12-28 2018-07-01 大陸商江蘇恆瑞醫藥股份有限公司 氮雜雙環基取代的三唑類衍生物、其製備方法及其在醫藥上的應用
CN111094272B (zh) * 2018-06-20 2022-05-27 江苏恒瑞医药股份有限公司 一种otr抑制剂的可药用盐、晶型及制备方法
CN113004250B (zh) * 2019-12-19 2022-07-26 上海森辉医药有限公司 一种制备取代的三唑衍生物的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063363A (ja) * 1998-08-12 2000-02-29 Yamanouchi Pharmaceut Co Ltd 新規なトリアゾール誘導体
AU2000223275A1 (en) * 2000-02-08 2001-08-20 Yamanouchi Pharmaceutical Co..Ltd. Novel triazole derivatives
WO2001087855A1 (fr) * 2000-05-19 2001-11-22 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
ATE297913T1 (de) * 2001-07-05 2005-07-15 Pfizer Prod Inc Sulfonyl-heteroaryl-triazole als entzündungshemmende und analgetische mittel
EP1458381B1 (en) * 2001-12-20 2005-11-30 Applied Research Systems ARS Holding N.V. Triazoles as oxytocin antagonists

Also Published As

Publication number Publication date
MXPA06003158A (es) 2006-06-05
CA2539297C (en) 2010-07-20
NL1027084A1 (nl) 2005-03-24
NL1027084C2 (nl) 2006-01-24
WO2005028452A1 (en) 2005-03-31
PE20050950A1 (es) 2005-11-11
WO2005028452A9 (en) 2005-07-21
UY28524A1 (es) 2005-04-29
CA2539297A1 (en) 2005-03-31
JP2007505888A (ja) 2007-03-15
EP1673355A1 (en) 2006-06-28
TW200526606A (en) 2005-08-16
AR045791A1 (es) 2005-11-16
BRPI0414663A (pt) 2006-11-21

Similar Documents

Publication Publication Date Title
CR9219A (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
CR10566A (es) Compuestos heterociclicos adecuados para el tratamiento de enfermedades relacionadas con nivel elevado de lipidos
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
ECSP045410A (es) Nuevos derivados de piridazin-3(2h)-ona
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
CL2004002050A1 (es) Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros.
PA8557101A1 (es) Benzimidazoles
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
UY28342A1 (es) Nuevos compuestos
ES2183937T3 (es) Inhibidores de la adhesion celular.
BRPI0514736A (pt) inibidores do receptor sigma
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CR7899A (es) Compuestos de triciclicos inhbidores de proteina quinasa para mejorar la eficacia de agentes antienoplasticos y derivados de diazenpamdionilo como inhibidores de quinasa
UY28150A1 (es) Agentes terapeuticos
BRPI0511979A (pt) derivados de triazóis substituìdos como antagonistas de oxitocina, composição farmacêutica compreendendo os referidos derivados, bem como uso dos mesmos
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
RS51271B (sr) Čvrsta farmaceutska kompozicija koja sadrži donepezil hidrohlorid
GT200100153A (es) Compuestos de 1,4-dihidropiridina como antagonistas de bradiquinina.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
UY27894A1 (es) Derivados de cinamida.
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
HN2002000365A (es) Lactamas como antagonistas de taquiquininas